These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1785181)
1. [The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14]. Rudenko LG; Ramirez A; Barro M; Gushchina MI; Armanda RE; Ermachenko TA; Romanova IuR; Grigor'eva EP; Aleksandrova GI; Lonskaia NI Vopr Virusol; 1991; 36(6):472-4. PubMed ID: 1785181 [TBL] [Abstract][Full Text] [Related]
2. [The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old]. Grigor'eva EP; Rekstin AR; Rudenko LG; Ramirez A; Barro M; Lisovskaia KV; Klimov AI; Aleksandrova GI Vopr Virusol; 1994; 39(1):26-9. PubMed ID: 8160445 [TBL] [Abstract][Full Text] [Related]
3. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity]. Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
6. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season]. Lupulescu E; Ioniţă E; Botez D; Matepciuc M; Tabra ME; Tecu C; Alexandrescu V; Munţiu A Bacteriol Virusol Parazitol Epidemiol; 1997; 42(1-2):110-2. PubMed ID: 9235136 [No Abstract] [Full Text] [Related]
7. [A comparative study of the inoculation properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8- to 15-year-old children]. Slepushkin AN; Obrosova-Serova NP; Burtseva EI; Govorkova EA; Rudenko LG; Vartanian RV; Vereshchinskiĭ AI; Musina MD; Lonskaia NI; Zazimko LA Vopr Virusol; 1991; 36(5):372-4. PubMed ID: 1803766 [TBL] [Abstract][Full Text] [Related]
8. [The evaluation of the reactogenicity and immunological activity of an inactivated 3-component influenza vaccine with an elevated hemagglutinin concentration in the inoculation dosage]. Marinich IG; Shadrin AS; Naĭkhin AN; Ivannikov IuG; Kuznetsov NP; Karogodina VI; Shcherbinskaia AM; Voronina EG; Stepankovskaia LD; Eliseeva IV Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):58-61. PubMed ID: 1950267 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476 [TBL] [Abstract][Full Text] [Related]
11. [Safety and immunogenicity of split vaccines of influenza viruses]. Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848 [TBL] [Abstract][Full Text] [Related]
14. [Safety and high immunogenicity for children 3 to 15 of a mono- and a divaccine from recombinant influenza A/Brazil /11/78 (H1N1) and A/Bangkok/1/79 (H3N2) viruses obtained from a special donor attenuation base--the cold-adapted virus A/Leningrad/134/47/57 (H2N2)]. Polezhaev FI; Budilovskiĭ GN; Garmashova LM; Romeĭko-Gurko IuR; Egorov AIu Vopr Virusol; 1983; 28(6):710-4. PubMed ID: 6670253 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
16. [Safety of an influenza-split-vaccine in children]. Schmitt-Grohé S; Banzhoff A; Klaassen B; Zielen S Klin Padiatr; 2001; 213(6):338-42. PubMed ID: 11713714 [TBL] [Abstract][Full Text] [Related]
17. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
18. [The formation of an immune response in volunteers inoculated with a live recombinant influenza vaccine]. Vorob'ev KV; Rudenko LG; Islamova IT; Grigor'eva EP; Egorov AIu; Ermachenko TA; Chepik EB; Zakharova NG; Karachentsev AM Vopr Virusol; 1991; 36(6):475-7. PubMed ID: 1785182 [TBL] [Abstract][Full Text] [Related]
19. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010 [TBL] [Abstract][Full Text] [Related]
20. [The results of state trials of inactivated influenza vaccines for children]. Vasil'eva RI; Smirnova LA; Rudenko LG; Drinevskiĭ VP; Tsaritsina IM Zh Mikrobiol Epidemiol Immunobiol; 1988 Mar; (3):49-54. PubMed ID: 2968738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]